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Routine varicella vaccination with one dose for chil-
dren of 11 to 14 months was recommended in Germany 
in 2004 to reduce disease incidence and severe com-
plications. A country-wide varicella sentinel surveil-
lance system was initiated in 2005 to detect trends of 
disease frequency and vaccine uptake and to evaluate 
the vaccination programme. A convenient sample of 
about 1,000 paediatricians and general practitioners 
was recruited to report on a monthly basis on varicella 
cases by age groups seen in their practice, and on vari-
cella vaccine doses administered. Sentinel data from 
April 2005 to March 2009 show a reduction of 55% of 
varicella cases in all ages; 63% in the age group 0-4 
years and 38% in 5-9 year-olds. The number of vac-
cine doses per reporting unit in all regions and phy-
sician groups increased during the same period. The 
number of reported cases as well as administered vac-
cines differed between physician groups and regions 
with different reimbursement policies. Where reim-
bursement was settled early and vaccine doses were 
increasing varicella cases started to decrease early as 
well. Besides reimbursement policies the availability 
and vaccination schedules influenced vaccine uptake. 
Sentinel surveillance provided valid data on trends 
for varicella associated morbidity, vaccine uptake and 
the age distribution of cases. The results confirm that 
following the introduction of routine varicella vaccina-
tion, varicella morbidity started to decline in Germany.
Introduction 
Varicella vaccination was introduced for all children 
older than 11 months in July 2004 in Germany [1]. Besides 
the age group (11-14 months) for which vaccination was 
recommended, closing of individual immunisation gaps 
was generally recommended for all children and ado-
lescents below 18 years of age. However, no systematic 
catch-up vaccination was foreseen. 
The main aim of the routine varicella vaccination pro-
gramme is the reduction of the burden of disease and 
of varicella related complications. However, this was 
not quantified [2]. Experiences from the United States 
(US), where varicella vaccination was introduced in 
the vaccination schedule already in 1996 [3,4], along 
with new data on the burden of disease [5] have influ-
enced the decision to introduce varicella vaccination in 
Germany. Recommendations include defined antigens 
but not specific vaccines. All available licensed vac-
cines can be used according to the official information 
provided by the manufacturer. At the time when the 
recommendation was issued, two monovalent varicella 
vaccines were available for the administration of one 
dose in early childhood and two doses in children over 
13 years of age. However, the costs for varicella vac-
cination were not covered by health insurances in all 
German federal states when varicella vaccination was 
recommended. Negotiations on reimbursement were 
successfully settled in spring 2006 for all states. In 
summer 2006, a combined vaccine against measles, 
mumps, rubella and varicella (MMRV) was licensed 
with a two-dose schedule and in 2008 licensures for 
the two monovalent vaccines were changed to two-
dose schedules for all ages. In July 2009 the recom-
mendation was changed to a two-dose schedule, with 
the second dose recommended at 15 to 23 months of 
age and with a minimum time interval of four to six 
weeks after the first dose. Thus, children in Germany 
have been vaccinated with different vaccines and dif-
ferent schedules since 2004. 
Paediatricians have a key role in the immunisation 
of children as well as in their healthcare (including 
diagnosis and treatment) in Germany. Ninety-five per 
cent of children see a paediatrician within the first 
two years of life [6]. This percentage decreases with 
increasing age to 25% for 14-17 year-olds and general 
practitioners (GPs) treat up to 53% of the adolescents 
[6]. Therefore these two physician groups seem to be 
most appropriate for monitoring varicella disease and 
varicella vaccination. Varicella is not a notifiable dis-
ease in Germany. Therefore a country-wide varicella 
sentinel surveillance system was implemented in April 
2005 in order to detect trends of disease frequency 
and vaccine uptake and to monitor the impact and the 
acceptance of the varicella vaccination programme.
This report reflects first results of the sentinel surveil-
lance and describes the association between vaccine 
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uptake and frequency of varicella cases after introduc-
tion of routine varicella vaccination as well as factors 
influencing the vaccine uptake. 
Methods 
Sentinel surveillance
The country-wide sentinel project on varicella and 
zoster epidemiology is managed in public-private-part-
nership by the German national public health institute, 
the Robert Koch Institute (RKI) which is responsible 
for the scientific management and, the German Green 
Cross (DGK), responsible for the recruitment of physi-
cians and data management. The vaccine manufac-
tures GlaxoSmithKline and Sanofi Pasteur MSD are 
financing the work at DGK, the RKI receives no finan-
cial support from the manufacturers. An independ-
ent scientific board gives scientific and operational 
advice for running the surveillance system. The system 
is called “working group on measles and varicella” 
(Arbeitsgemeinschaft Masern und Varizellen, AGMV) 
[7]. 
A convenient sample of over 1,000 primary care phy-
sicians was recruited, consisting of 60% paediatri-
cians and 40% GPs and accounting for about 15% of 
all German paediatricians and about 1% of all GPs in 
practice. Sentinel physicians of both groups are dis-
tributed across all 16 German federal states equally to 
the distribution of respective physicians in practice. 
Physicians participate on voluntary basis and neither 
doctors nor patients receive incentives. As patients 
are free to choose and change their physician and 
only a subset of physicians report to the sentinel, the 
population size under surveillance can not be defined. 
The sentinel is not population based and does aim at 
trends but not at incidence. 
Physicians provide aggregated numbers of varicella 
cases by age groups through monthly questionnaires. 
Age groups are divided as follows: <1 year, 1-4 years, 
5-9 years, 10-14 years, 20 years and older. Doctors doc-
ument the number of patients with varicella complica-
tions, vaccinated varicella cases and cases of herpes 
zoster. In addition, they report the monthly number of 
administered doses of varicella vaccines by first and 
second doses and since April 2007 doses are divided 
into monovalent and combined varicella vaccines. 
Zero-reporting and active reminders are included 
and the questionnaire provides case definitions. A 
case of varicella is defined as a person presenting at 
the physician’s practice with a clinical picture resem-
bling varicella, with skin exanthema and concomitant 
presentation of papules, blisters, pustules, crusts. 
Varicella complications are defined as varicella lead-
ing to hospitalisation, oral or parenteral antibiotic or 
antiviral therapy or as accompanied by neurological 
symptoms. Vaccinated varicella cases are persons vac-
cinated against varicella regardless of the time inter-
val between vaccination and onset of varicella. Herpes 
zoster is defined as appearance of blisters on an exan-
thematic skin, confined to a spinal or cranial nerve 
pathway, accompanied by at least one out of the follow-
ing symptoms: painful neuralgia of the affected region, 
fever, loss of appetite, myalgia, burning sensation 
Figure 1
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and/or itching of the affected region. Physicians are 
asked to report the number of patients they have seen 
at their practice in the respective month and catego-
ries. Laboratory confirmation is not required.
Descriptive Analysis
Data on varicella cases per age group and on varicella 
vaccinations by first and second doses were analysed 
and available from April 2005 to March 2009. Defining 
a varicella season as lasting from April until March of 
the following year, the surveillance covered four com-
plete varicella seasons (2005-6, 2006-7, 2007-8, 2008-
9). The number of reported varicella cases as well as 
the number of vaccine doses was related to the number 
of reporting physicians (units) as denominator in the 
respective month or season. Reporting physicians 
were grouped by speciality (paediatricians/GPs) and by 
region. Three regions were formed according to reim-
bursement policies (i) region 1: vaccination costs cov-
ered since general recommendation (cost regulations 
completed before 2005-6 season); (ii) region 2: reim-
bursement settled in 2005 (regulations completed dur-
ing 2005-6 season) and (iii) region 3: reimbursement 
settled in 2006 and partly restricted for specific age or 
vaccine only until March 2007 (regulations completed 
during 2006-7 season).
For data entry and data management MS Office ACCESS 
version 2003 was used, descriptive data analysis was 
carried out by SPSS version 16.
Results 
Varicella cases, vaccinations, 
reporting units over time
From April 2005 (start of season 1) until March 2009 
(end of season 4), a total of 83,181 varicella cases were 
reported by 1,178 physicians. During the same time 
289,327 first and 86,394 second doses of varicella vac-
cine were administered by sentinel physicians. 
Seasonal peaks of varicella disease occurred in spring. 
The peaks flattened over time, whereas the total 
number of reporting physicians remained fairly stable. 
A slight decrease in the number of reporting paediatri-
cians was balanced by an increase in the number of 
GPs (Figure 1). Paediatricians formed the majority of 
Table 1
Mean number of varicella vaccines and varicella cases per reporting unit and month by physician group and cost cover 
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CI: confidence interval; GP: general practitioner.
1 April to March of following year.
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reporting units over time. Between 396 and 518 pedia-
tricians and 156 to 275 GPs reported per month to the 
sentinel and the respective number of reporting units 
per season ranged from 499 to 635 pediatricians and 
260 to 381 GPs. The mean response rate was 76% for 
paediatricians and 54% for GPs and was stable in both 
groups over time. However, the proportion of paediatric 
units among all reporting units declined slightly from 
about 66% in the seasons 2005-6 and 2006-7 to about 
60% in 2007-8 and 2008-9 (Figure 1; Table 1). 
The number of monthly reported varicella cases per 
unit in all age groups together decreased from vari-
cella season 1 to season 4 from 2.85 to 1.29, which 
Figure 2
Average number of varicella cases per month and reporting unit by age over four varicella seasons, sentinel data, Germany, 
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Table 2
Total number of administered varicella vaccines as first and second, monovalent and combined doses and numbers per 
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is a reduction of 55% of cases. In the age group 0-4 
years cases per month and unit declined from 1.85 to 
0.69 (63%), and in the 5-9-year-olds from 0.85 to 0.53 
(38%). A reduction was also observed in the age group 
20 years and older. However, only 1% (n=784) of all 
reported cases belonged to this age group and a reduc-
tion from 0.05 to 0.01 (75%) was observed between 
varicella season 1 and 4 (Figure 2). In all varicella sea-
sons the majority of cases occurred in 0-4 year-olds. 
Proportions between age groups shifted over time; in 
season 1, 65% of all cases were seen in 0-4 year-olds 
and 30% in 5-9 year-olds, whereas the proportions 
were 53% and 41% respectively in season 4.
Cases and vaccinations by reporting 
units and cost cover groups 
The number of cases and administered vaccines per 
reporting unit and month differed by physician group 
and region; in all regions paediatricians adminis-
tered six to eight times more varicella vaccines and 
saw seven to nine times more varicella cases than 
GPs (Table 1). The total number of varicella cases per 
season (n=32,569; 21,384; 16,846 and 12,414 in vari-
cella seasons 1, 2, 3 and 4 respectively) as well as the 
mean number of cases per reporting unit and month 
decreased steadily over the four seasons. This trend 
was seen in case reports by both physician groups in all 
regions together and by GPs alone in each of the three 
regions, for paediatricians this trend was also found in 
regions 1 and 2 but not region 3 (Table 1). In all four 
seasons, in region 1 (region with earliest cost regula-
tion) all units together had less varicella cases per unit 
and month on average than in the other two regions; 
the highest number of cases per month was reported 
by paediatricians and GPs from region 3 (region, were 
cost regulation was settled last). The greatest differ-
ence in case reports between region 3 and the other 
two regions was calculated for seasons 2 and 3 in both 
physician groups. In the paediatric units of region 
1 a decrease of cases per unit was seen in season 2 
compared with season 1, and values remained stable 
on a low level in the following two seasons. In the GP 
units of region 1 the case numbers decreased over all 
four seasons but to a lesser extent than in the paedia-
trician group. A decrease over four seasons was also 
observed for both physician groups in region 2 with 
the above described differences between paediatri-
cians and GPs and starting from a lower level than in 
region 1. However, in region 3 a remarkable decrease 
in cases per paediatric units did not start until season 
4 and for GP units until season 3.   
In all four varicella seasons, paediatricians and GPs 
from region 1 and 2 administered more varicella doses 
than those from region 3, but this difference was most 
prominent in season 1. 
Vaccinations by physician groups over time
With 281,063 first and 82,663 second doses, 97% of all 
varicella vaccine doses were administered by paedia-
tricians (Table 2). The number of first doses per paedi-
atric reporting unit increased over three seasons and 
remained stable in season 4. With 35%, the increase 
was strongest from season 1 to 2. The number of second 
doses per paediatric unit increased steadily over time 
from 3.2 in season 1 to 100.4 in season 4. An increase 
in the total number of doses per unit was also seen in 
the GP group, however at lower level and divergent for 
first and second doses. Whereas first doses per unit 
increased from season 1 to season 2 and then slightly 
decreased over the following seasons, second doses 
per unit increased steadily over all four seasons. In 
season 3 less monovalent vaccine doses were adminis-
tered per unit compared with season 2. This was partly 
balanced by the use of MMRV. The number of MMRV 
per unit exceeded by far the number of first and second 
doses of monovalent vaccine in both physician groups. 
Whereas MMRV vaccine use has contributed most to 
the increase of second doses since season 2, there 
Table 3
Number of vaccinated cases, cases with complications and with Herpes zoster by physician group and by season, sentinel 
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was also a remarkable increase of monovalent second 
doses per unit from season 3 to 4.   
Other reporting categories
The number of varicella in vaccinated persons increased 
from 289 in varicella season 1 to 1,016 in season 4 and 
the proportion of vaccinated on all reported varicella 
cases went up from 0.9 to 8.2%. Although the upwards 
trend was seen by both physician groups, numbers and 
proportions of vaccinated patients were much higher in 
paediatricians reports in comparison to GPs (Table 3). 
The total number of reported complications went down 
from 142 cases (0.4% of all reported varicella cases) to 
26 (0.2%) over the four seasons and again this trend 
was more distinctive in paediatricians.
Concerning herpes zoster the crude reporting numbers 
in all four seasons were higher from GPs than from 
paediatricians corresponding to about four times more 
cases per reporting unit. However, a steady number of 
cases per unit were observed over time by both physi-
cian groups.   
Discussion
Germany is one of the few countries worldwide where 
varicella vaccination has been introduced in the rou-
tine childhood vaccination schedule. The most promi-
nent effects in the first four years after introduction 
of vaccination are the decrease in number of varicella 
cases and the increasing acceptance of vaccination [8]. 
Descriptive analysis of sentinel data provided evidence 
of a reduction in the number of cases in four consecu-
tive seasons following the introduction of the vacci-
nation programme. The decrease was greatest in 0-4 
year-olds, but the trend was seen in all age groups. 
Comparable results were reported from the US where 
after the introduction of varicella vaccination in the 
routine childhood vaccination programme in 1996 vari-
cella incidence declined substantially between 1995 
and 2000 in the sentinel regions [9].
The decrease in varicella morbidity in Germany can not 
be explained by secular trends. In absence of notifica-
tion data this can be demonstrated by data from hos-
pital discharges in the time from 1994 to 2004, the 
pre-vaccination era. The median of the annual number 
of hospitalised varicella cases was 1,957 and ranged 
from 1,806 cases in 2002 to 2,316 cases in 2004 [10]. 
In the three years after the general recommendation of 
varicella vaccination the annual number of hospitalised 
varicella cases steadily declined from 1,751 in 2005 to 
1,269 in 2007. The decline in number of hospitalised 
cases per 100,000 population was largest in the age 
group 1-4 years old (from >20 hospitalised varicella 
cases per 100,000 population in 1994-2004 to 10 in 
2007) and in infants (>30 in 1994-2004 to 21 in 2007). 
The decrease in varicella morbidity was observed in 
two independent sources and supported through com-
parison with data from the pre-vaccination era.
The rise in vaccine doses per reporting unit in all 
regions and all physician groups over the observed 
time period in the sentinel indicates an increased 
acceptance of varicella vaccination. Moreover, there 
are clear associations between reimbursements for 
vaccination and vaccine uptake on the one hand and 
the increase of vaccine uptake up to a stable level and 
the decrease of number of cases on the other. In the 
region were costs of vaccination were covered from the 
beginning of the programme the number of vaccines 
administered per physician were higher compared with 
the regions were reimbursement was settled at a later 
stage. The sentinel observations and descriptive sta-
tistics show, that when reimbursement was settled 
early and vaccine doses were increasing, the varicella 
cases started to decrease early as well. The time span 
between increasing number of vaccinations after cost 
regulations and the first visible effects on the number 
of varicella cases was about 1.5 seasons. Besides 
reimbursement policies the availability of vaccines and 
schedules of vaccination play an important role for vac-
cine uptake. While the increase of vaccinations in the 
first season after introduction of the programme was 
mainly due to negotiated reimbursement, the avail-
ability of MMRV has led to a growing number of second 
doses since autumn 2006. The administration of sec-
ond varicella vaccine doses was further accelerated in 
the season four due to a change in the licensed vacci-
nation schedule for monovalent varicella vaccines from 
one to two doses. 
With increasing numbers of vaccinated persons, the 
number of patients with varicella has decreased over 
time in Germany. The reduction was greatest in the 
group targeted for vaccination, i.e. young children. The 
observed proportion shift in the number of varicella 
cases from 0-4 year-olds towards 5-9 year-old children 
is a result of the greater reduction of varicella disease 
in toddlers and pre-school-age children in comparison 
to school-age children. A shift in the disease rates as 
given by number of cases per age and reporting unit 
towards older age groups has not been observed in the 
four seasons in the sentinel. Thus, a shift towards older 
age groups, associated with a higher risk of complica-
tions from varicella disease, has not been observed 
until now. Moreover, our results show that the number 
of complications has declined in the sentinel. 
With increasing numbers of vaccinated persons the 
potential for varicella disease in vaccinated persons is 
increasing and the proportion of vaccinated among all 
varicella cases will increase as well. This was shown in 
the US [13] and is now confirmed by the results of our 
sentinel surveillance in Germany. For further analysis 
case based data are necessary in order to differentiate 
between varicella shortly after vaccination and break-
through cases. Case-based data are also necessary to 
investigate the reported cases of herpes zoster more 
thoroughly. So far no trend in the frequency of herpes 
zoster was detected in the sentinel.
As the sentinel system is not population based, inci-
dence or vaccine coverage can not be estimated. For this 
purposes a notification system would be appropriate. 
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Although passive reporting (as for instance by notifica-
tions) is known to underestimate the total number of 
cases more than active reporting (as for instance this 
sentinel), the population under surveillance is clearly 
defined. Incidence by age and region could only be 
estimated if the denominator is known as in population 
based surveillance. Moreover, with further decreasing 
case numbers the sensitivity of the existing sentinel 
system might decrease. Therefore surveillance has to 
be adopted and one possible way would for instance be 
the introduction of varicella into statutory notifications 
in Germany.
In conclusion we can state that the varicella morbidity 
has started to decline and we are progressing towards 
reducing varicella morbidity and the overall burden of 
disease which are the main aims of the vaccination 
programme. Sentinel surveillance provides valid data 
on trends in varicella and herpes zoster morbidity in 
Germany and the age distribution of varicella cases so 
far. Furthermore, the sentinel seems to be appropriate 
to generate hypotheses for further investigations. If 
notification of varicella can not be implemented in the 
future, additional epidemiological data are needed to 
confirm sentinel results at population level and chang-
ing the current sentinel structures could ensure reli-
able case detection in the next years.
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